Business
Futura Medical Notice of Preliminary Results 2021
Futura Medical Notice of Preliminary Results 2021.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 4718I\n Futura Medical PLC\n 14 April 2022\n \n \n \n \n \n \n \n \n \n \n 14 April 2022\n \n \n \n \n \n \n \n \n \n Futura Medical plc\n \n \n (\"Futura\" or the \"Company\")\n \n Notice of Preliminary Results 2021\n \n \n \n Futura Medical plc (AIM: FUM) (\"Futura\" or the \"Company\"), pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, will announce its preliminary results for the year ended 31 December 2021 on Tuesday, 26 April 2022.\n \n James Barder, Chief Executive Officer, Angela Hildreth, Finance Director and Chief Operating Officer, and Ken James, Executive Director and Head of R&D, will host a webcast for analysts on the day of the results, which will be made available within the investor centre section of the Company's website.\n \n \n -ENDS-\n \n For further information please contact:\n \n \n Futura Medical plc \n \n \n James Barder, Chief Executive \n \n \n Angela Hildreth, Finance Director and COO \n \n \n Email: \n \n [email protected]\n \n \n \n \n Tel: +44 (0) 1483 685 670 \n \n \n \n www.futuramedical.com\n \n \n \n \n \n \n Nominated Adviser and Sole Broker:\n \n Liberum\n \nRichard Lindley/ Phil Walker/ Kane Collings\nTel: +44 (0) 20 3100 2000\n \n For media enquiries please contact:\n Optimum Strategic Communications\n Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt\n Email: [email protected]\n Tel: +44 (0) 20 3922 0891\n \n Notes to editors\n \n \n About Futura Medical plc \n \n \n Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise prod...